HIV Clinical Trial
Official title:
Suubi+Adherence4Youth: Optimizing the Suubi Intervention for Adherence to HIV Treatment for Youth Living With HIV in Uganda
The study will test four economic empowerment intervention components to identify the combination that best enhance viral suppression. The study design is a 2-to-the 4 factorial experiment. The 2 represents the level of each component:0 (receive) or (don't receive) four components: 1) Financial Literacy Training (FLT); 2) Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs); 3) A manualized intervention for ART adherence and stigma reduction (Suubi Cartoon); and 4) Engagement with HIV treatment-experienced role models who share their lived experiences of HIV. Guided by the MOST framework, the study will test each of the four components' performance and their combinations on the primary outcome, viral suppression. Resulting in 16 unique conditions representing all possible combinations of the 4 components. The study will randomize at the level of health clinics (N=48). Clinics will be randomized to provide one of the 16 conditions, with 12 ALHIV (aged 11-17 years) enrolled per clinic, yielding main effects and interaction effects for the 4 components on sustained viral suppression. Sustained viral suppression is defined as an undetectable viral load on all 12-, 24- and 36-month follow-up assessments.
Status | Recruiting |
Enrollment | 576 |
Est. completion date | July 31, 2027 |
Est. primary completion date | July 31, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 11 Years to 17 Years |
Eligibility | Inclusion Criteria: Adolescent: - living with HIV (confirmed by medical report and aware of status) - living within a family - being 11-17 years of age (at enrollment) - prescribed ART - enrolled in ART care at one of the 48 health clinics in the study districts. Health clinics would be eligible if they: - have existing procedures tailored to adolescent adherence (including adolescent-specific clinic days and peer counselling) - Accredited by the Uganda Ministry of Health as a provider of ART within the study districts. Exclusion Criteria: - Includes an inability to understand study procedures and participant rights as assessed during informed consent/assent process with the adolescent or parent. - If the adolescent or adult caregiver presents with emergency needs (e.g., hospitalization), needed care will be secured, rather than study participation |
Country | Name | City | State |
---|---|---|---|
Uganda | International Center for Child Health and Development | Masaka |
Lead Sponsor | Collaborator |
---|---|
Washington University School of Medicine | National Institute of Mental Health (NIMH), University of California, San Francisco |
Uganda,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in ART knowledge and ART adherence | Change in adolescent Self reported medication adherence. This will be measured using the Adherence and retention in care questionnaire focusing on the pharmacy refills, pill counts and missed appointments at each assessment time. | Baseline 12, 24 and 36 month follow-up | |
Other | Reductions in internalized stigma | Reductions in internalized stigma will be measured using the Social Impact Scale on a range of 24 - 96, with higher scores indicating higher levels of internalized stigma. | Baseline 12, 24 and 36 month follow-up | |
Other | Sexual negotiation and communication skills | Ability to negotiate safe sex practices measured using the Sexual Communication Scale. Responses are summed and scored on a range of 20 - 100, with higher scores representing greater levels of communication. | Baseline 12, 24 and 36 month follow-up | |
Other | Change in mental health-hopelessness symptoms | Hopelessness will be measured using the Beck Hopelessness Scale. The study will assess the mean scores over time. The total score range is between 0 - 20, with a higher score indicating higher levels of child hopelessness. | Baseline 12, 24 and 36 month follow-up | |
Other | Change in depressive symptoms | Depression will be measured using the Center for Epidemiological Studies-Depression Scale (CES-D). The total score range is between 0 - 60, with higher scores indicating the presence of more symptomatology. | Baseline 12, 24 and 36 month follow-up | |
Other | Change in HIV Stigma | Change in HIV stigma will be measured using the Negative Self-image sub-scale of HIV Stigma Scale. The total score range is between 40 - 160 with higher scores indicating higher levels of perceived HIV-associated stigma. | Baseline 12, 24 and 36 month follow-up | |
Other | Positive HIV Identity | HIV Positive Identity Scale | Baseline 12, 24 and 36 month follow-up | |
Other | Problem solving of HIV care logistics | Self-reported questionnaires | Baseline 12, 24 and 36 month follow-up | |
Other | Self-esteem | Self esteem will be measured using Rosenberg Self-Esteem Scale. The study will assess the mean scores over time. The total score range between10 - 40, with a higher score indicating high levels of child self esteem. | Baseline 12, 24 and 36 month follow-up | |
Other | Social support | Change in social support will be measured by Social Support Behavior Scale. | Baseline 12, 24 and 36 month follow-up | |
Other | Engagement and retention of HIV care metrics | The degree to which a patient feels engaged/disengaged from HIV care will be measured using the HIV Index of Engagement on a range of 10 - 50, with higher scores indicating better engagement. | Baseline 12, 24 and 36 month follow-up | |
Primary | Achievement of Viral Suppression | Change in viral suppression will be assessed using viral load (VL) data collected from health clinic records. VL will be dichotomized between undetectable /suppression (VL< 40 copies/ml) and detectable/failed viral suppression (VL > =40 copies/ml) levels at each assessment time. | Baseline 12, 24 and 36 month follow-up | |
Primary | Cost-Effectiveness Analyses | Cost-effectiveness analyses measuring the cost of achieving an agreed upon benefit, such as cost of staff time, supplies, overhead of IDA's, as measured by admin review and project records. | Baseline 12, 24 and 36 month follow-up | |
Secondary | Financial Literacy | Change in Financial Literacy knowledge will be measured using the Financial Literacy Knowledge item, with higher scores indicating higher financial literacy. | Baseline 12, 24 and 36 month follow-up | |
Secondary | Financial management skills | Change in financial management skills will be measured using the Attitudes about Saving Scale, with higher scores indicating greater financial management skills. | Baseline 12, 24 and 36 month follow-up | |
Secondary | Engagement with financial institutions | Change in engagement with financial institutions will be measured using the frequency of deposits and withdrawals by data from bank statements. | Baseline 12, 24 and 36 month follow-up | |
Secondary | Change in confidence to save | Change in confidence to save will be measured using the Financial Literacy Knowledge item, with higher scores indicating higher confidence to save. | Baseline 12, 24 and 36 month follow-up | |
Secondary | Change in motivation to save | Motivation to save will be measured using the Financial Literacy Knowledge item, with higher scores indicating higher motivation to save. | Baseline 12, 24 and 36 month follow-up | |
Secondary | Change in savings amount and Investment in IGA | Change in savings amount and investment measured by data from bank statements | Baseline 12, 24 and 36 month follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |